MedTrace Logo

Study of FP-1039 in Subjects With Endometrial Cancers

NCT01244438 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-12-13

No results posted yet for this study

Summary

An open-label, non-randomized, single arm study to assess the safety, tolerability, and pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly starting at a dose of up to 16 mg/kg.

Conditions

  • Endometrial Cancers With FGFR2 Mutations

Interventions

DRUG

FP-1039

FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Five Prime Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Harold Keer, MD, PhD · Five Prime Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-06-30
Completion
2012-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01244438 on ClinicalTrials.gov